Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case

BACKGROUND: Ronapreve demonstrated clinical application in post-exposure prophylaxis, mild/moderate disease and in the treatment of seronegative patients with severe COVID19 prior to the emergence of the Omicron variant in late 2021. Numerous reports have described loss of in vitro neutralisation ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatham, Lee, Kipar, Anja, Sharp, Joanne, Kijak, Edyta, Herriott, Joanne, Neary, Megan, Box, Helen, Toledo, Eduardo Gallardo, Valentijn, Anthony, Cox, Helen, Pertinez, Henry, Curley, Paul, Arshad, Usman, Rajoli, Rajith KR, Rannard, Steve, Stewart, James, Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811901/
https://www.ncbi.nlm.nih.gov/pubmed/35118468
http://dx.doi.org/10.1101/2022.01.23.477397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811901/
https://www.ncbi.nlm.nih.gov/pubmed/35118468
http://dx.doi.org/10.1101/2022.01.23.477397

Ejemplares similares